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Alteplase for Acute Ischemic Stroke in Patients 
Aged >80 Years
Pooled Analyses of Individual Patient Data
Erich Bluhmki , PhD; Thierry Danays, MD; Gabriele Biegert, PhD; Werner Hacke, MD; Kennedy R. Lees, MD
BACKGROUND/PURPOSE: Expert guidelines specify no upper age limit for alteplase for thrombolysis of acute ischemic stroke 
(AIS) but, until recently, European regulatory criteria restricted its use to patients aged 18 to 80 years. We performed pooled 
analyses of randomized controlled trial (RCT) and registry data to evaluate the benefit-risk profile of alteplase for AIS among 
patients aged >80 years to support a regulatory application to lift the upper age restriction.
METHODS: Individual patient data were evaluated from 7 randomized trials of alteplase (0.9 mg/kg) versus placebo or open 
control for AIS, and the European SITS-UTMOST registry database. Clinical outcomes, including good functional outcome 
(score 0–1, modified Rankin Scale day 90 or Oxford Handicap Score day 180), were evaluated in the full RCT and registry 
populations, and specified age-based subgroups (≤80 or >80 years) who met existing European regulatory criteria for 
alteplase, excluding upper age restriction.
RESULTS: Regardless of treatment allocation, 90-day mortality was lower among RCT patients aged ≤80 versus >80 years 
who otherwise met existing European regulatory criteria (246/2405 [10.2%] versus 307/1028 [29.9%], respectively). Among 
patients aged >80 years, alteplase versus placebo was associated with a higher proportion of good stroke outcome (modified 
Rankin Scale score 0–1; 99/518 [19.1%] versus 67/510 [13.1%]; P=0.0109) and similar 90-day mortality (153/518 [29.5%] 
versus 154/510 [30.2%]; P=0.8382). The odds of a good stroke outcome following alteplase allocation in the full RCT 
population were independent of age (P=0.7383). Good stroke outcome was reported for almost half (4821/11 169 [43.2%]) 
of the patients who received alteplase in routine practice. Outcomes in routine practice supported those achieved in RCTs.
CONCLUSIONS: Alteplase for AIS has a positive benefit-risk profile among patients aged >80 years when administered according 
to other regulatory criteria. Alteplase for AIS should be evaluated on an individual benefit-risk basis.
Key Words: alteplase ◼ elderly ◼ ischemic stroke ◼ recombinant tissue-type plasminogen activator ◼ thrombolysis
The clinical benefits of intravenous alteplase (recombinant tissue plasminogen activator) for thrombolytic treatment of acute ischemic stroke 
(AIS) are well established. However, key aspects of its 
regulatory approval differ by region.1 For example, no 
upper age limit is stated in the US product label, but 
treatment must be initiated within 3 hours of stroke 
onset.2 Alteplase is approved for use in Europe within 
4.5 hours of stroke onset but, until recently, regula-
tory criteria restricted its use to patients aged 18–80 
years.1,3
See related article, p XXX
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Approximately one-third of acute strokes occur among 
people aged ≥80 years.4,5 However, elderly patients were 
represented poorly in early clinical trials of thrombolysis 
for AIS. Subsequent initiatives have provided additional 
data on this population, including the randomized IST-3 
(Third International Stroke Trial),6 controlled compari-
son analyses,5,7 and several large observational studies, 
including the SITS-UTMOST (Safe Implementation of 
Thrombolysis in Upper Time Window Monitoring Study).8–
14 Clinical trial and observational data consistently sup-
port the use of alteplase for AIS among patients aged 
>80 years.6,13,15
Expert management guidelines issued by the Euro-
pean Stroke Organisation and American Stroke Asso-
ciation/American Heart Association recommend that 
alteplase is administered within 4.5 hours of stroke symp-
tom onset and no longer specify an upper age limit.16–19 
Closer alignment of regulatory criteria with clinical guide-
lines could allow more patients to receive a potentially 
beneficial therapy for AIS.1,5,20
We performed pooled analyses of randomized trial 
and registry data to evaluate the benefit-risk profile of 
alteplase for AIS among elderly patients who otherwise 
met existing European regulatory criteria. These data 
were used to support a regulatory application to lift the 
upper age restriction for use of alteplase for AIS.
METHODS
Anonymized data used in these analyses can be made available 
in line with the Boehringer Ingelheim Policy on Transparency 
and Publication of Clinical Study Data (https://trials.boeh-
ringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/
com_EN/documents/Policy.pdf). Institutional ethics review 
was not required.
Individual patient data were available from 9 random-
ized controlled trials (RCTs) of intravenous alteplase ver-
sus placebo or open control for AIS (n=6756).6,21–27 Data 
on all patients (n=721) from 2 studies were excluded from 
our analysis (as described in the Data Supplement).22,26 All 
randomized patients from the remaining 7 trials (ATLANTIS 
A, ATLANTIS B, ECASS II, ECASS III, IST-3, NINDS A, and 
NINDS B) conducted across Australasia, Europe, Central, and 
North America were considered for inclusion.6,21,23–25,27 Data 
were evaluated using statistical methods and outcomes simi-
lar to those described previously.1,28,29
Briefly, we used logistic regression, stratified by trial, to 
model the common linear dependence of the log odds of a 
good stroke outcome on allocation to alteplase, age, base-
line stroke severity (National Institutes of Health Stroke 
Scale [NIHSS] score, excluding distal motor function [range 
0–42]) and treatment delay (all linear variables) and interac-
tions between allocation to alteplase and each of these other 
baseline covariates. Missing continuous baseline variables 
(age, NIHSS score, and treatment delay) were imputed using 
the overall mean for each study. Missing end points related to 
stroke outcome were imputed by last observation carried for-
ward/worst case imputation. We used likelihood ratio tests to 
assess the extent to which treatment delay, age, and stroke 
severity (baseline NIHSS score) affected proportional treat-
ment effects; statistical significance was tested by comparing 
the change in deviance between 2 nested models that differed 
only by interaction term.
To assess the treatment effect of alteplase for AIS in 
elderly patients, 2 subgroups who received treatment in line 
with European regulatory criteria (excluding upper age restric-
tion) were specified based on age (≤80 or >80 years). Patients 
were excluded if: symptom onset to treatment was >4.5 hours; 
the stroke was considered severe (assessed clinically [NIHSS 
score >25] or by appropriate imaging); there was a history of 
both stroke and diabetes mellitus; systolic BP >185; diastolic 
BP >110 mm Hg; or blood glucose <50 or >400 mg/dL.
Key trial outcomes were compared among the full RCT popula-
tion and subgroups who met European regulatory criteria (exclud-
ing upper age restriction) aged ≤80 or >80 years. Prespecified 
end points were good stroke outcome at day 90/180; death 
≤7 days; death ≤90 days; symptomatic intracranial hemorrhage 
(sICH); fatal ICH (parenchymal hemorrhage type 2 and death) ≤7 
days; and death ≤7 days not related to parenchymal hemorrhage 
type 2 bleeding. Data are presented with 95% CI.
sICH was defined in the current analyses, among IST-3 
patients, as symptomatic neurological deterioration or death 
with clear evidence of significant ICH on post-randomization 
scan (or autopsy) ≤2 days after treatment. In all other tri-
als evaluated, sICH was defined as per SITS-MOST (SITS-
Monitoring Study) criteria (parenchymal hemorrhage type 2 
with NIHSS score deterioration ≥4 from baseline or death 
≤36 hours after treatment).30
Functional stroke outcome was assessed using the Oxford 
Handicap Score at 6 months in IST-3, and modified Rankin 
Scale (mRS) score at 3 months in all other studies.6 The Oxford 
Handicap Score and mRS are very similar assessment tools.31 
For patients who died 92 to 180 days poststroke in IST-3, an 
Oxford Handicap Score of 6 at day 90 was changed to mRS 
score 5 to align with evaluations in other studies. A good stroke 
outcome was defined as a score of 0–1 on mRS at day 90 or 
Oxford Handicap Score at day 180 (and reported herein as 
mRS score at day 90/180).
The distribution of functional stroke outcome among those 
who received alteplase or placebo in the full RCT population 
and age-defined subgroups was visualized. Shift analyses of 
Nonstandard Abbreviations and Acronyms
AIS acute ischemic stroke
IST-3 Third International Stroke Trial
mRS modified Rankin Scale
NIHSS  National Institutes of Health Stroke 
Scale
RCT randomized controlled trial
sICH symptomatic intracranial hemorrhage
SITS-MOST SITS-Monitoring Study
SITS- 
UTMOST  Safe Implementation of Thrombolysis in 
Upper Time Window Monitoring Study
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mRS scores at day 90/180 were conducted and unadjusted 
Cochran-Mantel-Haenszel test used to compare outcomes 
with alteplase versus placebo in age-defined subgroups.
To provide a real-life perspective, we also analyzed data 
from the European SITS-UTMOST registry.8 Data were col-
lected prospectively from May 2012, at centers across Europe, 
on consecutive patients who received alteplase regardless of 
whether they met approved treatment criteria.
Similar to the evaluation of individual patient data from 
RCTs described above, analyses were conducted on data on 
a patient subset from the European SITS-UTMOST registry 
who met existing European regulatory criteria (excluding upper 
age restriction) for use of alteplase in AIS; 2 subgroups were 
defined based on patient age (≤80 or >80 years). No imputa-
tion of missing values was applied; available data were reported 
using the number of patients with a recorded observation as 
the denominator for each end point. The distribution of mRS 
scores at day 90/180 among patients who received alteplase 
in the full RCT and SITS-UTMOST registry populations and 
age-defined subgroups were also visualized. No comparative 
statistical analyses were conducted on SITS-UTMOST data.
Estimated differences between groups are reported with 
95% CI. P values <0.05 were considered statistically significant.
RESULTS
Pooled Analysis of Randomized Trial Data
The full RCT population comprised 6035 patients from 
7 randomized trials of alteplase (0.9 mg/kg) versus pla-
cebo or open control for AIS.6,21,23–25,27 Of these, 3026 
patients received alteplase and 3009 received placebo 
or open control. More than a quarter of the full RCT pop-
ulation (1699/6035) were aged >80 years (Table I in 
the Data Supplement).
Logistic Regression Analyses of the Effects of 
Alteplase on Stroke Outcomes
In the full RCT population, alteplase administration within 
4.5 hours after symptom onset had a beneficial effect 
on good stroke outcome (Figure 1A). Earlier administra-
tion of alteplase was associated with increased odds of 
good stroke outcome and greater proportional benefit 
(P=0.0203 for interaction).
The odds of a good stroke outcome follow-
ing alteplase allocation were independent of age 
(P=0.7383 for interaction; Figure 1B). The 95% CIs 
widen at extremes of age and cross the odds ratio=1 
reference line beyond 90 years.
A significant interaction between baseline NIHSS 
score and alteplase allocation on stroke outcome was 
not detected (P=0.2898; Figure 1C). However, CIs sup-
port a beneficial effect of alteplase on stroke outcome 
among patients with a baseline NIHSS score ≥5.
Subgroup Analyses of the Effect of Alteplase on 
Stroke Outcomes
Two subgroups who met European regulatory criteria 
(excluding upper age restriction) were specified based 
on age: ≤80 years (alteplase n=1182; placebo n=1223); 
>80 years (alteplase n=518; placebo n=510). The most 
common reason for exclusion was administration of 
alteplase >4.5 hours after stroke onset (n=2030).
Baseline demographic and disease characteristics of 
the full RCT population and age-based subgroups who 
met European regulatory criteria (excluding upper age 
restriction) are presented in Table I in the Data Supple-
ment. Patients aged >80 years had more severe strokes 
(mean [SD] baseline NIHSS score 13.2 [6.3] versus 11.2 
[5.7]) and higher rates of comorbidities than did younger 
patients. Baseline characteristics are described in the 
Data Supplement.
Data on key clinical trial end points are presented in 
Table 1. Regardless of treatment allocation, overall (90-
day) mortality was substantially lower among patients 
aged ≤80 years versus >80 years who otherwise met 
existing European regulatory criteria (10.2% [95% CI, 
9.0–11.4] versus 29.9% [95% CI, 27.1–32.7]).
Among patients aged ≤80 years, alteplase versus pla-
cebo was associated with a higher proportion of good 
stroke outcomes (44.8% [95% CI, 41.9–47.6] versus 
35.9% [95% CI, 33.2–38.6]; P<0.0001), higher rates 
of sICH (2.6% [95% CI, 1.7–3.5] versus 0.5% [95% CI, 
0.1–0.9]; P<0.0001), and comparable 90-day mortality 
(9.8% [95% CI, 8.1–11.5] versus 10.6% [95% CI, 8.9–
12.4]; P=0.5448).
Likewise, among patients aged >80 years, alteplase 
versus placebo was associated with a higher proportion 
of good stroke outcomes (19.1% [95% CI, 15.7–22.5] 
versus 13.1% [95% CI, 10.2–16.1]; P=0.0109), higher 
rates of sICH (3.7% [95% CI, 2.0–5.3] versus 0.4% 
[95% CI, 0.0–0.9]; P=0.0002) and similar 90-day mor-
tality (29.5% [95% CI, 25.6–33.5] versus 30.2% [95% 
CI, 26.2–34.2]; P=0.8382).
Distribution of mRS Scores at Day 90/180
Distributions of mRS scores at day 90/180 for patients 
who received alteplase or placebo in the full RCT popula-
tion and age-defined subgroups are shown in Figure 2. 
Patients aged ≤80 years had better outcomes than did 
older patients, regardless of treatment allocation. A posi-
tive shift toward better outcomes with alteplase versus 
placebo can be seen in the full RCT population and both 
age-defined subgroups (and both time-to-treatment 
windows [0–3 and 3–4.5 hours]). Shift analyses of 
mRS scores at day 90/180 showed significantly better 
outcomes with alteplase (0–4.5 hours) versus placebo 
among patients aged ≤80 years (P=0.0001) and >80 
years (P=0.0106) who otherwise met existing European 
regulatory criteria for alteplase for AIS.
Analysis of SITS-UTMOST Registry Data
Data were available on 14 086 patients (the full registry 
population) who received alteplase for AIS at 94 centers. 
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Figure 1. Estimated effect of alteplase vs placebo on the odds of good stroke outcome by time to treatment, patient age, and 
stroke severity.  
A, Time to treatment (P=0.0203 for interaction). B, Patient age (P=0.7383 for interaction). C, Stroke severity (baseline National Institutes of 
Health Stroke Scale [NIHSS] score; P=0.2898 for interaction). Good stroke outcome was defined as a modified Rankin Scale score of 0 to 1 at 
day 90/180. Each plot is adjusted for treatment delay, age, NIHSS score, and interactions between allocation to alteplase and each of these other 
covariates, and stratified by study; solid line, estimated odds ratio; dashed lines, 95% CIs, NIHSS indicates National Institutes of Health Stroke Scale.
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Most patients (11 911/14 086) met existing European 
regulatory criteria, excluding upper age restriction. From 
these, 2 subgroups were identified based on patient age: 
9491 were aged ≤80 years; 2420 were aged >80 years.
Patients aged >80 years, who otherwise met exist-
ing European regulatory criteria had more severe strokes 
(mean [SD] baseline NIHSS scores 12.9 [6.3] versus 
11.0 [6.1], respectively) and higher rates of comorbidities 
than did younger patients. Baseline data are described in 
the Data Supplement.
Outcomes among the full registry population and 
defined subgroups are shown in Table 2. Overall, almost 
half (4821/11 169; 43.2%) of patients who received 
alteplase in routine practice (and had a recorded out-
come at day 90) had a good stroke outcome. Patients 
aged ≤80 years had a higher proportion of good stroke 
outcomes (3700/7487 [49.4%; 95% CI, 48.3–50.6] 
versus 514/1929 [26.6%; 95% CI, 24.7–28.6]), and 
lower 90-day mortality (837/7700 [10.9%; 95% CI, 
10.2–11.6] versus 576/1985 [29.0%; 95% CI, 27.0–
31.0]) versus older patients who otherwise met existing 
European regulatory criteria. Similar rates of sICH were 
reported in both subgroups (152/9317 [1.6%; 95% CI, 
1.4–1.9] aged ≤80 years versus 33/2379 [1.4%; 95% 
CI, 0.9–1.9] aged >80 years).
Distribution of mRS Scores at Day 90/180 
Among Alteplase-Treated Patients in the RCT 
and the SITS-UTMOST Registry Populations
Raw mRS score distributions at day 90/180 for alteplase-
treated patients in the RCT and the SITS-UTMOST reg-
istry populations, and age-defined subgroups are shown 
in Figure 3 (for 0–3 hour and 3–4.5 hour time-to-treat-
ment periods). Patients aged ≤80 years tended to have 
better outcomes versus older patients in both time-to-
treatment periods. Reported outcomes appeared slightly 
better among patients in the registry versus RCT popula-
tions (in both time-to-treatment periods). For example, a 
smaller proportion of patients aged >80 years had high 
mRS scores (5–6) at day 90/180 in the registry versus 
clinical trial setting.
Table 1. Key Clinical Trial End Points for Patients Who Received Alteplase or Placebo for AIS in the Full RCT Population and 
Specified Age-Defined Subgroups Who Met European Regulatory Criteria
End Point
Full RCT Population
Specified Subgroups*
Met European Regulatory Criteria,  
Aged ≤80 y
Met European Regulatory Criteria  
Other Than Aged >80 y
Alteplase (n=3026) Placebo (n=3009) Alteplase (n=1182) Placebo (n=1223) Alteplase (n=518) Placebo (n=510)
Good stroke outcome†
 Yes, n (%; 95% CI) 1016  
(33.6; 31.9 to 35.3)
867  
(28.8; 27.2 to 30.4)
529  
(44.8; 41.9 to 47.6)
439  
(35.9; 33.2 to 38.6)
99  
(19.1; 15.7 to 22.5)
67  
(13.1; 10.2 to 16.1)
 Difference, % (95% CI) 4.8 (2.4 to 7.1); P<0.0001 8.9 (5.0 to 12.8); P<0.0001 6.0 (1.5 to 10.5); P=0.0109
Death within 7 d
 Yes, n (%; 95% CI) 236 (7.8; 6.8 to 8.8) 175 (5.8; 5.0 to 6.7) 61 (5.2; 3.9 to 6.4) 50 (4.1; 3.0 to 5.2) 55 (10.6; 8.0 to 13.3) 40 (7.8; 5.5 to 10.2)
 Difference, % (95% CI) 2.0 (0.7 to 3.3); P=0.0025 1.1 (−0.6 to 2.8); P=0.2434 2.8 (−0.8 to 6.3); P=0.1325
Death within 90 d
 Yes, n (%; 95% CI) 526  
(17.4; 16.0 to 18.7)
501  
(16.7; 15.3 to 18.0)
116  
(9.8; 8.1 to 11.5)
130  
(10.6; 8.9 to 12.4)
153  
(29.5; 25.6 to 33.5)
154  
(30.2; 26.2 to 34.2)
 Difference, % (95% CI) 0.7 (−1.2 to 2.6); P=0.4513 −0.8 (−3.2 to 1.6); P=0.5448 −0.7 (−6.3 to 4.9); P=0.8382
sICH‡
 Yes, n (%; 95% CI) 109 (3.6; 2.9 to 4.3) 16 (0.5; 0.3 to 0.8) 31 (2.6; 1.7 to 3.5) 6 (0.5; 0.1 to 0.9) 19 (3.7; 2.0 to 5.3) 2 (0.4; 0.0 to 0.9)
 Difference, % (95% CI) 3.1 (2.4 to 3.8); P<0.0001 2.1 (1.1 to 3.1); P<0.0001 3.3 (1.6 to 5.0); P=0.0002
Fatal ICH (PH2 or cause of death hemorrhage) within 7 d
 Yes, n (%; 95% CI) 84 (2.8; 2.2 to 3.4) 11 (0.4; 0.1 to 0.6) 22 (1.9; 1.1 to 2.6) 3 (0.2; 0.0 to 0.5) 18 (3.5; 1.9 to 5.1) 2 (0.4; 0.0 to 0.9)
 Difference, % (95% CI) 2.4 (1.8 to 3.0); P<0.0001 1.6 (0.8 to 2.4); P<0.0001 3.1 (1.4 to 4.8); P=0.0004
Death within 7 d not related to PH2 or cause of death hemorrhage
 Yes, n (%; 95% CI) 152 (5.0; 4.2 to 5.8) 164 (5.5; 4.6 to 6.3) 39 (3.3; 2.3 to 4.3) 47 (3.8; 2.8 to 4.9) 37 (7.1; 4.9 to 9.4) 38 (7.5; 5.2 to 9.7)
 Difference, % (95% CI) −0.4 (−1.6 to 0.7); P=0.4881 −0.5 (−2.0 to 0.9); P=0.5107 −0.3 (−3.5 to 2.9); P=0.9047
P values calculated using Fisher exact test (2-sided). IST-3 indicates Third International Stroke Trial; PH2, type 2 parenchymal hemorrhage; RCT, randomized 
controlled trial; and sICH, symptomatic intracranial hemorrhage.
*Two subgroups of patients who met European regulatory criteria (excluding upper age restriction) were specified based on age.
†Good stroke outcome defined as modified Rankin Scale score 0–1 at day 90/180.
‡sICH defined as: symptomatic neurological deterioration or death with clear evidence of significant intracranial hemorrhage on postrandomization scan (or autopsy) 
≤2 d after treatment among IST-3 patients; per Safe Implementation of Thrombolysis in Stroke Monitoring Study criteria for all other patients.
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DISCUSSION
Our pooled analyses of individual patient data from ran-
domized trials and registry studies support a positive ben-
efit–risk profile of intravenous alteplase for AIS, among 
patients aged >80 years, when administered according 
to other European regulatory criteria.
Treatment with alteplase in placebo-controlled trials 
was associated with a greater proportion of good stroke 
outcome and significantly better functional outcomes 
overall. The benefits of alteplase were consistent among 
patient populations aged ≤ or >80 years and were 
achieved with comparable rates of 90-day mortality ver-
sus placebo.
A
B
Figure 2. Distribution of modified Rankin Scale (mRS) scores at day 90/180 after acute ischemic stroke (AIS) in the full 
randomized controlled trial (RCT) population and specified age-defined subgroups (aged ≤80 y or >80 y who otherwise met 
existing European regulatory criteria for alteplase for AIS).  
A, Time to treatment 0 to 3 h. B, Time to treatment 3 to 4.5 h.
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Similarly, the odds of a good outcome of AIS fol-
lowing alteplase treatment versus control were inde-
pendent of age. Although, the wide CIs (because of 
restricted patient numbers) at extremes of age limit 
assessment of any interaction.
Patients aged >80 years, regardless of treatment 
allocation, had worse functional outcomes and higher 
mortality rates following AIS compared with younger 
patients. This is likely to be an effect of increasing age 
and comorbidity and greater stroke severity. None-
theless, the positive benefit-risk profile of thromboly-
sis using alteplase for AIS was consistent across the 
patient age range.
Our registry data provide reassurance that outcomes 
among patients aged >80 years who received alteplase 
for AIS in routine clinical practice correspond well with 
those in RCTs. The incidence of sICH (1.4% versus 3.7%) 
and overall mortality (29.0% versus 29.5%) following 
thrombolysis of patients aged >80 years who otherwise 
met European regulatory criteria was not increased in 
routine practice versus clinical trials.
Registry data echo the functional outcomes 
achieved with alteplase for AIS in randomized trials. 
Moreover, our data suggest a positive shift toward bet-
ter outcomes among patients treated in routine prac-
tice versus a clinical trial setting although no statistical 
analyses were performed.
In total, we evaluated outcomes of almost 3000 
patients aged >80 years who otherwise met European 
regulatory criteria and received alteplase for AIS in ran-
domized trials or in clinical practice. This is the largest 
pooled analysis of alteplase for AIS in this elderly popu-
lation to date. As for any pooled analysis, our results are 
dependent on the quality of the primary research. There-
fore, we selected datasets for inclusion in our analysis 
based on strict criteria.
Other key strengths of the current analyses include 
our access to individual patient data, the use of common 
definitions for most outcomes, and stratification of logis-
tic regression analyses to retain the influence of indi-
vidual trials on outcomes. As such, we think that these 
analyses provide an accurate estimate of the effect size 
of alteplase for AIS in patients aged >80 years.
Our findings are in line with previously published 
analyses. The Stroke Thrombolysis Trialists’ Collabora-
tors Group have reported numerous meta-analyses of 
Table 2. Outcomes Among Patients Who Received Alteplase for AIS in the Full SITS-UTMOST Registry 
Population and Age-Defined Subgroups Who Met European Regulatory Criteria*
Outcome
Full Registry  
Population
Met European Regulatory Criteria, 
Aged ≤80 y
Met European Regulatory Criteria, 
Other Than Aged >80 y
Alteplase (n=14 086) Alteplase (n=9491) Alteplase (n=2420)
Good stroke outcome†
 Yes, n/N (%; 95% CI) 4821/11 169 (43.2) 3700/7487 (49.4; 48.3 to 50.6) 514/1929 (26.6; 24.7 to 28.6)
 Difference, % (95% CI)  22.8 (20.5 to 25.0); P<0.0001
Death within 7 d
 Yes, n/N (%; 95% CI) 890/13 873 (6.4) 447/9350 (4.8; 4.3 to 5.2) 239/2388 (10.0; 8.8 to 11.2)
 Difference, % (95% CI)  −5.2 (−6.5 to −3.9); P<0.0001
Death within 90 d
 Yes, n/N (%; 95% CI) 1798/11 461 (15.7) 837/7700 (10.9; 10.2 to 11.6) 576/1985 (29.0; 27.0 to 31.0)
 Difference, % (95% CI)  −18.1 (−20.3 to −16.0); P<0.0001
sICH‡
 Yes, n/N (%; 95% CI) 230/13 807 (1.7) 152/9317 (1.6; 1.4 to 1.9) 33/2379 (1.4; 0.9 to 1.9)
 Difference, % (95% CI)  0.2 (−0.3 to 0.8); P=0.4612
Fatal ICH (PH2 or cause of death hemorrhage) within 7 d
 Yes, n/N (%; 95% CI) 207/14 014 (1.5) 112/9441 (1.2; 1.0 to 1.4) 44/2411 (1.8; 1.3 to 2.4)
 Difference, % (95% CI)  −0.6 (−1.2 to −0.1); P=0.0207
Death within 7 d not related to PH2 or cause of death hemorrhage
 Yes, n/N (%; 95% CI) 683/14 014 (4.9) 335/9441 (3.5; 3.2 to 3.9) 195/2411 (8.1; 7.0 to 9.2)
 Difference, % (95% CI)  −4.5 (−5.7 to −3.4); P<0.0001
All data are n (%); P values calculated using Fisher exact test (2-sided). IST-3 indicates Third International Stroke Trial; PH2, type 2 parenchymal 
hemorrhage; sICH, symptomatic intracranial hemorrhage; and SITS-UTMOST, Safe Implementation of Thrombolysis in Upper Time Window 
Monitoring Study.
*Patients with missing end point are excluded from the denominator.
†Good stroke outcome defined as modified Rankin Scale score 0 to 1 at day 90/180.
‡sICH defined as symptomatic neurological deterioration or death with clear evidence of significant intracranial hemorrhage on postrandomization 
scan (or autopsy) ≤2 d after treatment among IST-3 patients; per Safe Implementation of Thrombolysis in Stroke Monitoring Study criteria for all 
other patients.
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data on up to 6756 patients who received alteplase or 
placebo/open control in RCTs.1,15,28,32 Thrombolysis for 
AIS was associated with an increased risk of sICH soon 
after treatment.28,32 Nonetheless, alteplase had a positive 
effect on stroke outcomes regardless of patient age.1,15,28 
A beneficial effect of thrombolysis on functional stroke 
outcome was demonstrated among patients aged >80 
years in 2 large nonrandomized, controlled comparison 
analyses.5,7 Similar benefits of alteplase for AIS were 
reported among patients aged ≤80 or >80 years in a 
subsequent Cochrane review (odds ratio of death/depen-
dence 0.85 [95% CI, 0.76–0.95]; P=0.004 versus odds 
ratio 0.80 [95% CI, 0.64–0.99]; P=0.04, respectively).33
Inclusion of patients in the current analyses followed 
strict regulatory criteria and, therefore, builds on exist-
ing understanding of the benefits of alteplase for AIS in 
elderly patients. As intended, our data were submitted for 
regulatory consideration.
A combined body of evidence led to agreement by Euro-
pean regulatory authorities in 2018 to rescind the upper 
age restriction on the use of alteplase in AIS.3 As such, 
alteplase is now approved for use in Europe to treat patients 
aged >80 years.3 Elderly patients should be selected care-
fully based on their general health and baseline neurologi-
cal status.3 Regulatory criteria for the use of alteplase for 
AIS are now better aligned with clinical guidelines.
A
B
Figure 3. Distribution of mRS scores at day 90/180 after AIS among patients who received alteplase in the full RCT and SITS-
UTMOST registry populations, and specified age-defined subgroups (aged ≤80 y or >80 y who otherwise met existing European 
regulatory criteria for alteplase for AIS).  
A. Time to treatment 0–3 h. B. Time to treatment 3–4.5 h. AIS, acute ischemic stroke; mRS, modified Rankin Scale; RCT, randomized controlled 
trial; SITS-UTMOST, Safe Implementation of Thrombolysis in Upper Time Window Monitoring Study.
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CONCLUSIONS
These pooled analyses of individual patient data from 
randomized trials and registry studies indicate that 
intravenous alteplase for AIS has a positive benefit-risk 
profile in patients aged >80 years, when administered 
according to other European regulatory criteria. These 
data are in line with the findings of numerous previous 
reports. Thrombolysis treatment for patients presenting 
with AIS should be evaluated on an individual benefit-
risk basis. Importantly, age alone is no longer a barrier to 
alteplase treatment for AIS.
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